2011, a year rich
in change for Sanofi »

Message from Serge Weinberg
Chairman of the Board of Directors

Our Group completed two ventures that significantly modified
our sphere of activities.

The most important was the acquisition of Genzyme. This was initiated in 2010 and completed in April 2011 when Genzyme, a leader in the field of rare diseases, came under the umbrella of Sanofi. Completing the Genzyme deal was a major investment, close to €15 billion. But it allows the Group to increase its presence in biotechnologies which hold great promise for the future and acquire a very interesting research portfolio. The second operation was the 100% integration of Merial into the Group. In the past, we only held 50% of this leader in animal health.

In addition to these two strategic actions, several other acquisitions – particularly in China and India – also strengthened our position in emerging markets which delivered 30.3% of Group sales and experienced growth of more than 10% in 2011. The Emerging Markets growth platform, together with the others: Diabetes, Consumer Healthcare, Animal Health, Human Vaccines and Innovative Products, will be the key for the future success of Sanofi.

Read the full interview in the interactive annual review